Phase 2, randomized, double‐blind, placebo‐controlled, 4‐week study to evaluate the safety and efficacy of OPA‐ 15406 (difamilast), a new topical selective phosphodiesterase type‐4 inhibitor, in Japanese pediatric patients aged 2–14 years with atopic dermatitis
Saeki, Hidehisa, Baba, Naoko, Oshiden, Kazuhide, Abe, Yuji, Tsubouchi, HidetsuguLanguage:
english
Journal:
The Journal of Dermatology
DOI:
10.1111/1346-8138.15137
Date:
November, 2019
File:
PDF, 467 KB
english, 2019